Clinical Trial Search

Primary: Overall Response Rate (ORR) Per Response Evaluation Criteria in Solid Tumors (RECIST) Criteria Version 1.0 — 13.5; 13.5 Percentage of participants

Primary: Changes in Thyroid Nodule Size — 0.241361; 0.954909; 0.422121; 0.104143 mL

Primary: Increased Radioiodine Uptake — 6 Participants

Primary: Time to Tumor Progression — 334; 176 days

Primary: Best Overall Response Rate — 9.4; 0; 30 percentage of participants

Primary: Overall Response (OR) — 0; 3; 3; 1 Participants

Primary: Objective Response Rate (ORR) — 1 Participants

Primary: P16 Evaluation in Ovarian Germ Cell Tumors — 7; 4; 0; 6 units on a scale — p=0.001

Primary: Progression Free Survival — 241 days

Primary: Restoration of Radioiodine Uptake in Metastatic Lesions as Demonstrated by Diagnostic Whole-body Scanning After Decitabine Administration — 0 participants

Primary: Best Overall Response Rate in TKI-Naive Participants — 42.3 percentage of participants

Primary: Percentage of Participants With Transient Hypoparathyroidism, as Defined by a Day 1 Serum Parathyroid Hormone (PTH) Level of < 10 pg/ml — 24.1; 33.3 percentage of…

Primary: Overall Response Rate (in Cohorts 1-3) — 49; 14; 0 percentage of participants

Primary: Percentage of Participants With Objective Response (OR) — 38.3 Percentage of participants

Primary: Maximum Tolerated Dose (MTD) of Cisplatin (Phase I) — 100 mg/m^2

Primary: Change in Tumor Size — 4.7 cm

Primary: Maximum Tolerated Dose (MTD) [Phase I Dose Escalation] — 5 mg

Primary: Progression-free Survival (PFS) Based on Central Assessment Incl. Clinical Progression Due to Bone Irradiation — 329; 175 Days — p=<0.0001

Primary: Stiffness of Thyroid Nodules as Measured by Elastography — 2.7; 3.8; 2.7 meters/second

Primary: Dose Limiting Toxicity — 0; 1; 2 Participants

Primary: Primary Efficacy Parameters of Sensitivity of High Resolution Magnetic Resonance Imaging With Lymphotrophic Superparamagnetic Nanoparticles (LSN MRI) — 85.5 percentage…

Primary: Percentage of Participants With Local-regional Progression-free Survival — 15.2 percentage of all participants

Primary: RAI (Radioactive Iodine) Uptake and Tg (Thyroglobulin) Level Compared Pre and Post- Valproic Treatment — 6; 1; 1; 0 Participants

Primary: Objective Tumor Response Rate Assessed by RECIST — 0 participants

Primary: Complete Response Rate (Cohort 1) — 0 percentage of participants

Primary: Response Rate — 17 Participants

Primary: Number of Participants With Response Per Responsive Evaluation Criteria in Solid Tumors Criteria (RECIST v1.0) — 17; 9; 11 Participants

Primary: To Determine the Efficacy (Best Response) of BAY 43-9006 (Objective Response Rate and Stable Disease) in Patients With Metastatic Thyroid Carcinoma. — 0; 16; 22; 1…

Primary: PET-CT Fusion Scanning Sensitivity — 49; 54 percentage of participants

Primary: Overall Survival Rate — 0 percentage of participants alive